期刊文献+

Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology 被引量:4

Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology
下载PDF
导出
摘要 Autoimmune diseases are affected by complex pathophysiology involving several cell types,cytokines,antibodies,and mimicking factors.Different drugs are used to ameliorate these autoimmune reactions,including nonsteroidal anti-inflammatory drugs(NSAIDs),corticosteroids,antiantibodies,and small molecular drugs(DMARDs),and they are clinically in vogue for diseases such as rheumatoid arthritis(RA).Nevertheless,low cost-effectiveness,reduced efficacy,adverse effects,and patient nonresponse are unappealing factors driving the development of new drugs such as iguratimod.Iguratimod is primarily used to ameliorate RA in Japanese and Chinese clinics.However,its efficacy against other autoimmune ailments is also under intense investigation,and the number of investigations is becoming increasingly larger with each passing day.The articular structure comprises synovium,ligaments,and bone.The latter is more complex than the others since it regulates blood cells and autoimmunity in addition to providing skeletal support to the body.Therefore,its protection is also of prime importance in RA and other autoimmune diseases.Herein,we have highlighted the role of iguratimod in autoimmune diseases and bone protection.We suggest that iguratimod’s unique mode of action compared with that of other DMARDs and its good patient response makes it a suitable antirheumatic and bone-protecting drug. Autoimmune diseases are affected by complex pathophysiology involving several cell types, cytokines, antibodies, and mimicking factors. Different drugs are used to ameliorate these autoimmune reactions, including nonsteroidal anti-inflammatory drugs(NSAIDs), corticosteroids, antiantibodies, and small molecular drugs(DMARDs), and they are clinically in vogue for diseases such as rheumatoid arthritis(RA). Nevertheless, low cost-effectiveness, reduced efficacy, adverse effects, and patient nonresponse are unappealing factors driving the development of new drugs such as iguratimod. Iguratimod is primarily used to ameliorate RA in Japanese and Chinese clinics. However, its efficacy against other autoimmune ailments is also under intense investigation, and the number of investigations is becoming increasingly larger with each passing day. The articular structure comprises synovium,ligaments, and bone. The latter is more complex than the others since it regulates blood cells and autoimmunity in addition to providing skeletal support to the body. Therefore, its protection is also of prime importance in RA and other autoimmune diseases.Herein, we have highlighted the role of iguratimod in autoimmune diseases and bone protection. We suggest that iguratimod’s unique mode of action compared with that of other DMARDs and its good patient response makes it a suitable antirheumatic and bone-protecting drug.
出处 《Bone Research》 SCIE CAS CSCD 2019年第4期327-337,共11页 骨研究(英文版)
基金 supported by the Natural Science Foundation of Shandong Province (ZR2012HM038) the Shenzhen Science and Technology Innovation Committee Fund (JCYJ2016033117365255) the China International Medical Foundation (Simcere-Z2014-06-2-1635) the China Torch Program (2013GH021476)
  • 相关文献

参考文献4

二级参考文献5

共引文献33

同被引文献20

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部